Clinical Trial Update: Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of dasatinib and osimertinib in advanced EGFR-mutant non-small cell lung cancer has been terminated with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Sprycel (dasatinib)
• TAGRISSO (osimertinib)

Snippet

Sponsor: Chul Kim | Conditions: EGFR Gene Mutation, Nonsmall Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-07-05